Informe del mercado de fabricación biofarmacéutica por cultivo celular (cultivo celular de mamíferos, cultivo celular microbiano), clase (anticuerpos monoclonales, proteínas recombinantes, interferón, factor estimulante de colonias de granulocitos (G-CSF), eritropoyetina, insulina humana recombinante, vacunas, hormonas de crecimiento humano (HGH)) y región 2024-2032

Informe del mercado de fabricación biofarmacéutica por cultivo celular (cultivo celular de mamíferos, cultivo celular microbiano), clase (anticuerpos monoclonales, proteínas recombinantes, interferón, factor estimulante de colonias de granulocitos (G-CSF), eritropoyetina, insulina humana recombinante, vacunas, hormonas de crecimiento humano (HGH)) y región 2024-2032

Report Format: PDF+Excel | Report ID: SR112025A14327

Language of the Report – English

Sin embargo, el informe puede estar disponible en español por un costo adicional.

1   Preface
2   Research Methodology and Market Definitions
3   Executive Summary
4   Global Biopharmaceutical Market: Key Trends

    4.1 Biopharmaceuticals are Growing Faster than Small Molecule Drugs
    4.2 Growth of Biosimilars will Push Volumes and Introduce New Players in this Market
    4.3 A Rich Biopharmaceutical Pipeline will Drive the Capacity Demand in the Coming Years
    4.4 Increasing Trends in Mergers and Acquisitions will Increase Redundant Capacities
    4.5 Increasing Focus on Personalized Medicines and High Value Low Volume Markets
    4.6 Higher Titers will Reduce Capacity Demand
    4.7 Growth in the Use of Cost Effective Disposable Technologies
    4.8 Despite Sufficient Global Capacity, Its Uneven Distribution will Continue to Spur Demand
5   Global Biopharmaceutical Market: Industry Performance
    5.1 Current and Historical Sales Trends
    5.2 Market Breakup by Region
    5.3 Market Breakup by Expression Systems
    5.4 Market Breakup by Product Type
    5.5 Market Outlook
     5.6 SWOT Analysis
         5.6.1 Strengths
         5.6.2 Weaknesses
         5.6.3 Opportunities
         5.6.4 Threats
     5.7 Value Chain Analysis
     5.8 Porter’s Five Forces Analysis
         5.8.1 Overview
         5.8.2 Bargaining Power of Buyers
         5.8.3 Bargaining Power of Suppliers
         5.8.4 Degree of Competition
         5.8.5 Threat of New Entrants
         5.8.6 Threat of Substitutes
  6   Regional Biopharmaceutical Market Analysis
      6.1 United States
         6.1.1 Current and Historical Sales Trends
         6.1.2 Market Outlook
     6.2 Canada
         6.2.1 Current and Historical Sales Trends
         6.2.2 Market Outlook
    6.3 United Kingdom
         6.3.1 Current and Historical Sales Trends
         6.3.2 Market Outlook
    6.4 Germany
         6.4.1 Current and Historical Sales Trends
         6.4.2 Market Outlook
    6.5 France
         6.5.1 Current and Historical Sales Trends
         6.5.2 Market Outlook
    6.6 Italy
         6.6.1 Current and Historical Sales Trends
         6.6.2 Market Outlook
    6.7 Spain
         6.7.1 Current and Historical Sales Trends
         6.7.2 Market Outlook
    6.8 Russia
         6.8.1 Current and Historical Sales Trends
         6.8.2 Market Outlook
     6.9 Brazil
         6.9.1 Current and Historical Sales Trends
         6.9.2 Market Outlook
    6.10 Australia
         6.10.1 Current and Historical Sales Trends
         6.10.2 Market Outlook
7   Global Biopharmaceutical Manufacturing Industry
    7.1 Current and Historical Manufacturing Capacity Trends
    7.2 Impact of COVID-19
    7.3 Market Breakup by Region
        7.3.1 North America
            7.3.1.1 Current and Historical Manufacturing Capacity Trends
            7.3.1.2 Market Outlook
        7.3.2 Europe
            7.3.2.1 Current and Historical Manufacturing Capacity Trends
            7.3.2.2 Market Outlook
        7.3.3 Asia
            7.3.3.1 Current and Historical Manufacturing Capacity Trends
            7.3.3.2 Market Outlook
    7.4 Market Breakup by Cell Culture
        7.4.1 Mammalian Cell Culture
            7.4.1.1 Key Market Drivers
            7.4.1.2 Current and Historical Sales Trends
            7.4.1.3 Current and Historical Manufacturing Capacity Trends
            7.4.1.4 Market Breakup by Region
            7.4.1.5 Market Breakup by Product Type
            7.4.1.6 Key Players
            7.4.1.7 Market Outlook
        7.4.2 Microbial Cell Culture
            7.4.2.1 Key Market Drivers
            7.4.2.2 Current and Historical Sales Trends
            7.4.2.3 Current and Historical Manufacturing Capacity Trends
            7.4.2.4 Market Breakup by Product
            7.4.2.5 Market Breakup by Region
            7.4.2.6 Key Players
            7.4.2.7 Market Outlook
    7.5 Market Breakup by Class
        7.5.1 Monoclonal Antibodies
            7.5.1.1 Current and Historical Sales Trends
            7.5.1.2 Market Outlook
        7.5.2 Recombinant Proteins
            7.5.2.1 Current and Historical Sales Trends
            7.5.2.2 Market Outlook
        7.5.3 Interferon
            7.5.3.1 Current and Historical Sales Trends
            7.5.3.2 Market Outlook
        7.5.4 Granulocyte Colony-Stimulating Factor (G-CSF)
            7.5.4.1 Current and Historical Sales Trends
            7.5.4.2 Market Outlook
        7.5.5 Erythropoietin
            7.5.5.1 Current and Historical Sales Trends
            7.5.5.2 Market Outlook
        7.5.6 Recombinant Human Insulin
            7.5.6.1 Current and Historical Sales Trends
            7.5.6.2 Market Outlook
        7.5.7 Vaccines
            7.5.7.1 Current and Historical Sales Trends
            7.5.7.2 Market Outlook
        7.5.8 Human Growth Hormones (HGH)
            7.5.8.1 Current and Historical Sales Trends
            7.5.8.2 Market Outlook
    7.6 Market Outlook
8   Competitive Landscape
    8.1 Market Breakup by Manufacturer Type
        8.1.1 Product Companies
        8.1.2 Contract Manufacturers
    8.2 Key Player Profiles
        8.2.1 AbbVie Inc.
            8.2.1.1 Company Overview
            8.2.1.2 Key Financials
        8.2.2 Amgen Inc.
            8.2.2.1 Company Overview
            8.2.2.2 Key Financials
        8.2.3 Biogen Inc.
            8.2.3.1 Company Overview
            8.2.3.2 Key Financials
        8.2.4 Eli Lilly and Company
            8.2.4.1 Company Overview
            8.2.4.2 Key Financials
        8.2.5 F. Hoffmann-La Roche Ltd. 
            8.2.5.1 Company Overview
            8.2.5.2 Key Financials
        8.2.6 Johnson & Johnson Services Inc.
            8.2.6.1 Company Overview
            8.2.6.2 Key Financials
        8.2.7 Merck & Co. Inc.
            8.2.7.1 Company Overview
            8.2.7.2 Key Financials
        8.2.8 Novo Nordisk A/S
            8.2.8.1 Company Overview
            8.2.8.2 Key Financials
        8.2.9 Pfizer Inc.
            8.2.9.1 Company Overview
            8.2.9.2 Key Financials
        8.2.10 Sanofi S.A.
            8.2.10.1 Company Overview
            8.2.10.2 Key Financials          

Informe del mercado de fabricación biofarmacéutica por cultivo celular (cultivo celular de mamíferos, cultivo celular microbiano), clase (anticuerpos monoclonales, proteínas recombinantes, interferón, factor estimulante de colonias de granulocitos (G-CSF), eritropoyetina, insulina humana recombinante, vacunas, hormonas de crecimiento humano (HGH)) y región 2024-2032
Purchase Options New Year Sale
Benefits of Customization
  • Personalize this research
  • Triangulate with your data
  • Get data as per your format and definition
  • Gain a deeper dive into a specific application, geography, customer, or competitor
  • Any level of personalization

Get in Touch With Us

UNITED STATES

Phone: +1-631-791-1145

INDIA

Phone: +91-120-433-0800

UNITED KINGDOM

Phone: +44-753-714-6104

Email: sales@imarcgroup.com

Client Testimonials